Day One Biopharmaceuticals (DAWN) Return on Capital Employed (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed Return on Capital Employed for 4 consecutive years, with 0.28% as the latest value for Q4 2025.
- Quarterly Return on Capital Employed rose 14.0% to 0.28% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.28% through Dec 2025, up 14.0% year-over-year, with the annual reading at 0.26% for FY2025, 27.0% up from the prior year.
- Return on Capital Employed for Q4 2025 was 0.28% at Day One Biopharmaceuticals, up from 0.36% in the prior quarter.
- The five-year high for Return on Capital Employed was 0.24% in Q2 2025, with the low at 1.08% in Q2 2024.
- Average Return on Capital Employed over 4 years is 0.49%, with a median of 0.46% recorded in 2024.
- The sharpest move saw Return on Capital Employed crashed -59bps in 2024, then soared 85bps in 2025.
- Over 4 years, Return on Capital Employed stood at 0.42% in 2022, then plummeted by -34bps to 0.56% in 2023, then grew by 26bps to 0.42% in 2024, then surged by 32bps to 0.28% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.28%, 0.36%, and 0.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.